Dermagnostix at the EADV Congress in Berlin
Live demo on October 13th, 12.30 pm
Hall 4.2, booth E05
The demand for precision diagnostics
Skin diseases impair patients’ quality of life more drastically than cancer and diabetes²
Your point-of-need molecular solution
Groundbreaking translational research meets cutting-edge technology – Dermagnostix provides unique diagnostic tests for unmet clinical needs in dermatology on a fully automated portable laboratory. With PsorX (CE-IVD), Dermagnostix offers the first in-class molecular test for differential diagnosis of psoriasis and eczema.
Simple diagnostic tools for complex skin diseases
Ensuring maximum usability, the user only needs to place the sample into the LabDisk and insert the LabDisk into the Analyzer.
Results are delivered in only 45 min to 2 hours enabling physicians to make timely decisions about their patients’ therapies.
Each LabDisk contains only minimum amounts of reagents and materials due to microfluidics design.
All advantages of centrifugal microfluidics are exploited, enabling reliable, objective and valid results.
Point of need
Timely diagnoses where they are needed: Get objective and valid results anywhere and at any time.
Product of Germany
Our technology is developed, produced and tested in Germany.
Meet the Dermagnostix team
Get our news
DxPx US, AACC ConferenceIndustry & Investor Partnering Conference, July 30 – August 1, 2023, Chicago, IL
EADV Congress 2023European Academy of Dermatology and Venereology, Berlin 11-14 October 2023
Digi Derma Start-up Café des BVDDMarketplace of Interactions, Berlin 28 October 2023
- Flohr C, Hay R (2021): Putting the burden of skin diseases on the global map. Br J Dermatol 184(2): 189-190.
- Montero-Vílchez T, Sánchez-Díaz M, Martínez-López A, Arias-Santiago S (2021): Quality of Life in Patients with Skin Disease and Their Cohabitants. Health-Related Quality of Life Measurement Tools, Predictors and Modifiers. IntechOpen.
- Augustin M, Glaeske G, Hagenström K (2021): Neurodermitisreport - Prävention, Versorgung und Innovation.